Arcellx (ACLX) Non-Current Assets (2021 - 2025)
Arcellx's (ACLX) quarterly Non-Current Assets came in at $141.8 million in Q4 2025, up 26.59% year-on-year from $112.0 million in Q4 2024, and down 22.86% quarter-over-quarter from $183.8 million in Q3 2025.
Arcellx (ACLX) Non-Current Assets (2021 - 2025) Analysis & Trends
Arcellx's Non-Current Assets history runs 5 years deep, the most recent figure standing at $141.8 million for Q4 2025.
- On a quarterly basis, Non-Current Assets rose 26.59% year-over-year to $141.8 million in Q4 2025; TTM through Dec 2025 was $574.8 million, a 16.06% decrease from a year earlier, with the FY2025 full-year figure at $141.8 million, up 26.59% from the prior year.
- Non-Current Assets retreated to $141.8 million in Q4 2025 per ACLX's latest filing, from $183.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $204.1 million in Q2 2024 and bottomed at $16.0 million in Q4 2021.
- The 5-year median for Non-Current Assets is $108.8 million (2023), against an average of $105.3 million.
- Across the five-year window, Non-Current Assets surged 270.25% in 2024 and tumbled 50.81% in 2025, its largest moves.
- Year by year, Non-Current Assets stood at $16.0 million in 2021, then soared by 193.96% to $47.0 million in 2022, then jumped by 131.65% to $108.8 million in 2023, then rose by 2.99% to $112.0 million in 2024, then advanced by 26.59% to $141.8 million in 2025.
- Per Business Quant, the three latest ACLX Non-Current Assets figures stand at $141.8 million (Q4 2025), $183.8 million (Q3 2025), and $155.2 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 141.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 141.81 Mn |
| Sep 30, 2025 | 183.84 Mn |
| Jun 30, 2025 | 155.19 Mn |
| Mar 31, 2025 | 93.93 Mn |
| Dec 31, 2024 | 112.02 Mn |
| Sep 30, 2024 | 177.61 Mn |
| Jun 30, 2024 | 204.10 Mn |
| Mar 31, 2024 | 190.96 Mn |
| Dec 31, 2023 | 108.77 Mn |
| Sep 30, 2023 | 122.76 Mn |
| Jun 30, 2023 | 65.46 Mn |
| Mar 31, 2023 | 51.58 Mn |
| Dec 31, 2022 | 46.95 Mn |
| Sep 30, 2022 | 47.02 Mn |
| Jun 30, 2022 | 49.58 Mn |
| Mar 31, 2022 | 22.60 Mn |
| Dec 31, 2021 | 15.97 Mn |